Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MRSN

MRSN - Mersana Therapeutics Inc Stock Price, Fair Value and News

$29.08 
Market Closed

6/100

MRSN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

MRSN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$23.23

Target 3M

$26.14

Target 6M

$24.68

MRSN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRSN Price Action

Last 7 days

-0.1%

Last 30 days

4.3%

Last 90 days

250.7%

Trailing 12 Months

-17.0%

MRSN RSI Chart

MRSN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRSN Valuation

Market Cap

145.4M

Price/Earnings (Trailing)

-2.07

Price/Sales (Trailing)

4.38

EV/EBITDA

-1.31

Price/Free Cashflow

-1.95

MRSN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$23.23

Target 3M

$26.14

Target 6M

$24.68

MRSN Fundamentals

MRSN Revenue

Revenue (TTM)

33.2M

Rev. Growth (Yr)

-12.61%

Rev. Growth (Qtr)

260.24%

MRSN Earnings

Earnings (TTM)

-70.1M

Earnings Growth (Yr)

34.4%

Earnings Growth (Qtr)

68.95%

MRSN Profitability

EBT Margin

-207.28%

Return on Equity

117.71%

Return on Assets

-111.8%

Free Cashflow Yield

-51.16%

MRSN Investor Care

Shares Dilution (1Y)

1.16%

Diluted EPS (TTM)

-13.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202534.0M34.8M33.2M0
202438.3M29.9M34.8M40.5M
202332.3M38.7M40.8M36.9M
20224.5M8.2M11.9M26.6M
2020028.4M14.6M828.0K
201948.6M44.6M43.3M42.1M
201816.3M16.8M12.7M10.6M
201725.8M23.3M26.3M17.5M
201614.1M17.8M21.5M25.2M
201500010.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Mersana Therapeutics Inc

MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEmersana.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES228

Mersana Therapeutics Inc Frequently Asked Questions

MRSN is the stock ticker symbol of Mersana Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 06 2026, market cap of Mersana Therapeutics Inc is 145.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MRSN's fair value in chart for subscribers.

The fair value guage provides a quick view whether MRSN is over valued or under valued. Whether Mersana Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mersana Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRSN.

As of Tue Jan 06 2026, MRSN's PE ratio (Price to Earnings) is -2.07 and Price to Sales (PS) ratio is 4.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRSN PE ratio will change depending on the future growth rate expectations of investors.